Non-Small Cell Lung Carcinoma (NSCLC) Market Snapshot (2023 to 2033)

The global non-small cell lung carcinoma (NSCLC) market is expected to garner a market value of US$ 8.25 Billion in 2023 and is expected to accumulate a market value of US$ 21.40 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033. The growth of the non-small cell lung carcinoma (NSCLC) market can be attributed to the rising prevalence of NSCLC across the globe due to increasing air pollution and smoking habits amongst people. The market for non-small cell lung carcinoma (NSCLC) registered a CAGR of 7.3% in the historical period 2017 to 2022.

The presence of a strong pipeline for non-small cell lung carcinoma is projected to propel the growth over the coming years. For instance, fruquintinib (HMPL-013), a drug developed to treat advanced non-small cell lung carcinoma is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, the development of such advanced treatments is expected to drive the market during the forecast period.

Report Attribute Details
Estimated Base Year Value (2021) US$ 7.5 Billion
Expected Market Value (2023) US$ 8.25 Billion
Anticipated Forecast Value (2033) US$ 21.4 Billion
Projected Growth Rate (2023 to 2033) 10% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Non-small Cell Lung Carcinoma (NSCLC) Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for non-small cell lung carcinoma (NSCLC) reflected a value of 7.3% during the historical period, 2018 to 2022.

Several market players halted their clinical trials due to a financial crisis in the year. For instance, according to clinicaltrials.gov in July 2021, it was observed that more than 200 interventional studies were halted from March to April 2020 due to the emergence of COVID-19. Additionally, fluctuation in the market is mainly due to the disruption in the supply chain of raw materials and end products.

According to an article published in September 2020 titled The impact of the COVID-19 pandemic on lung cancer patients, at the Fifth Affiliated Hospital of Sun Yat-sen University, around 95 patients out of 161 had delayed their return visits in April 2020, and 47 cases finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments. Thus, the market for non-small cell lung carcinoma (NSCLC) is expected to register a CAGR of 10% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Non-Small cell Lung Carcinoma (NSCLC) Market?

Smoking and tobacco consumption increasing the number of patients suffering from non-small cell lung carcinoma

The American Cancer Society estimates that lung cancer is one of the highest death-causing diseases in the world. Covid-19 significantly affected non-small cell lung cancer-related clinical trials across the world. However, cancer care and maintaining high standards of diagnosis and treatment have been the major priorities of national healthcare bodies and international healthcare systems worldwide.

The growing number of patients suffering from non-small cell lung cancer across the world is one of the key drivers of the growth of the market. This is majorly due to the increasing number of people with unhealthy habits such as smoking, tobacco & alcohol consumption, high dose of supplements, and sedentary lifestyle across the world. Additionally, increasing pollution level in the air is also one of the major factors contributing to the increase in the number of patients.

Approvals of Medication for Lung Carcinoma Propelling Market Growth

As per the statistics provided by the World Health Organization (WHO) updates from February 2022, 2.2 Billion patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of the share of all lung cancer patients. Thus, the availability of a large patient base and a further increasing number of non-small cell lung carcinoma patients resulted in the high demand for treating the patients.

Recent approvals of new drugs are expected to accelerate market growth during the forecast period. For instance, In March 2021, the FDA approved Pfizer’s Lorbrena (lorlatinib) to treat ALK-positive NSCLC patients in the USA. Additionally, in October 2021, Ventana Medical Systems, Inc. received United States of America FDA approval for VENTANA PD-L1 (SP263) Assay as a companion diagnostic device to select patients for Tecentriq. Hence, recent new drug approvals and the launch of companion diagnostics to select targeted patients are responsible for the growth of the market during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Non-Small cell Lung Carcinoma (NSCLC) Market?

Longer Duration for approval of Medication hampering Growth of Market

The expensive nature of research and development of medication to treat patients is derailing the progress of the market. In addition, the financial burden added by the COVID-19 pandemic is playing a key role in hindering the growth of the market. Furthermore, the time taken for approval of drugs along with certain medications not being approved in spite of being in the clinical trial phase for a longer duration is hampering the overall growth of the non-small cell lung carcinoma market.

Region-Wise Insights

Research and Development Activities Favoring Growth of Non-Small Cell Lung Carcinoma Market in North America?

Launch of new drugs creating Favorable treatment for non-small cell lung carcinoma in North America

North America is expected to maintain its dominance during the forecast period and is one of the most lucrative regions for the NSCLC market. This is due to the presence of a strong pipeline and research activities undertaken by various industry players and academic institutions.

Thus, North America is expected to account for the largest share of all the regions in 2023. This is attributed to the entry of newer drugs, high investment by players, acceptance of costly drugs, and increased government funding for research and development activities. Owing to the aforementioned reasons, North America is expected to possess a 40% market share for the non-cell lung carcinoma market in 2023.

Large Patient Pool Creating Lucrative Opportunities for Non-Small Cell Lung Carcinoma Market in Asia Pacific?

Less stringent regulator framework opening doors for medication development in the Asia Pacific

Asia Pacific is expected to be the second largest contributor in 2023 for the non-small lung cell carcinoma market. This is owing to the presence of less stringent regulatory procedures for approval and a large patient pool. Japan and China are expected to contribute the highest to the Asia Pacific region due to the availability of advanced drugs, a developed economy, and a large patient pool.

Pricing pressure by the governments of European countries is likely to affect the market negatively during the forecast period. For instance, in October 2016, the National Institute for Health and Care Excellence (NICE) disapproved funding for Opdivo, as it did not meet the required cost-to-benefit ratio. Thus, Asia Pacific is expected to possess a 35% market share for the non-small cell lung carcinoma market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Market Competition

Key players in the market are non-small cell lung carcinoma market AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline plc, Novartis, Pfizer Inc, Roche Holding AG, Sun Pharmaceutical Industries Ltd.

  • In June 2021, AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.
  • Pfizer, another key player in non-small cell lung carcinoma is focusing on investing in research and development in manufacturing medications depending on the ailment. Thus, the company plans to examine its medication through clinical trials for receiving approval.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 8.25 Billion
Market Value in 2033 US$ 21.4 Billion
Growth Rate CAGR of 10% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2017 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Type
  • Treatment
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East and Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Pfizer Inc.
  • AstraZeneca Plc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lily and Company
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Merck & Co. Inc.
  • Celgene Corp.
  • Sun Pharmaceutical Industries Ltd.
Customization Available Upon Request

Key Segments Profiled in the Non-Small cell Lung Carcinoma (NSCLC) Industry Survey

Type:

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neuroendocrine Tumors

Treatment:

  • Chemotherapy
  • Targeted Therapy
    • Bevacizumab (Avastin)
    • Nectiumumbab (Portrazza)
    • Ramucirumab (Cyramza)
  • Immunotherapy
    • Nivolumab (Opdivo)
    • Atezolizumab (Tecentrig)
  • Others

End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa

Frequently Asked Questions

At what rate did the non-small cell lung carcinoma (NSCLC) market flourish from 2017 to 2022?

From 2018 to 2022, the non-small cell lung carcinoma (NSCLC) market grew at a CAGR of 7.3%

What will be the growth rate of the global non-small cell lung carcinoma (NSCLC) market during the forecast period?

The global non-small cell lung carcinoma (NSCLC) market is expected to grow with a 10% CAGR from 2023 to 2033.

What will be the projected market size of the non-small cell lung carcinoma (NSCLC) market by 2033?

As of 2033, the non-small cell lung carcinoma (NSCLC) market is expected to reach US$ 21.40 Billion

How is the North America non-small cell lung carcinoma (NSCLC) market projected to grow in 2033?

North America is expected to possess 40% market share for non-small cell lung carcinoma (NSCLC) market in North America.

How is the Asia Pacific non-small cell lung carcinoma (NSCLC) market projected to grow in 2033?

Asia Pacific is expected to possess 35% market share for non-small cell lung carcinoma market.

Table of Content

1. Executive Summary | Non-Small Cell Lung Carcinoma (NSCLC) Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Adenocarcinoma

        5.3.2. Squamous Cell Carcinoma

        5.3.3. Large Cell Carcinoma

        5.3.4. Large Cell Neuroendocrine Tumors

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        6.3.1. Chemotherapy

        6.3.2. Targeted Therapy

            6.3.2.1. Bevacizumab (Avastin)

            6.3.2.2. Necitumumab (Portrazza)

            6.3.2.3. Ramucirumab (Cyramza)

        6.3.3. Immunotherapy

            6.3.3.1. Nivolumab (Opdivo)

            6.3.3.2. Atezolizumab (Tecentriq)

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Homecare

        7.3.3. Specialty Clinics

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia & Pacific

        8.3.5. East Asia

        8.3.6. Middle East and Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States of America

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Treatment

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Treatment

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Treatment

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Treatment

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Type

        11.2.3. By Treatment

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Treatment

        11.3.4. By End User

    11.4. Key Takeaways

12. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Australia

            12.2.1.6. New Zealand

            12.2.1.7. Rest of South Asia & Pacific

        12.2.2. By Type

        12.2.3. By Treatment

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Treatment

        12.3.4. By End User

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Type

        13.2.3. By Treatment

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Treatment

        13.3.4. By End User

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Type

        14.2.3. By Treatment

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Treatment

        14.3.4. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. United States of America

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Type

            15.1.2.2. By Treatment

            15.1.2.3. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Type

            15.2.2.2. By Treatment

            15.2.2.3. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Type

            15.3.2.2. By Treatment

            15.3.2.3. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Type

            15.4.2.2. By Treatment

            15.4.2.3. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Type

            15.5.2.2. By Treatment

            15.5.2.3. By End User

    15.6. United Kingdom

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Type

            15.6.2.2. By Treatment

            15.6.2.3. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Type

            15.7.2.2. By Treatment

            15.7.2.3. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Type

            15.8.2.2. By Treatment

            15.8.2.3. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Type

            15.9.2.2. By Treatment

            15.9.2.3. By End User

    15.10. India

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Type

            15.10.2.2. By Treatment

            15.10.2.3. By End User

    15.11. Malaysia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Type

            15.11.2.2. By Treatment

            15.11.2.3. By End User

    15.12. Singapore

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Type

            15.12.2.2. By Treatment

            15.12.2.3. By End User

    15.13. Thailand

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Type

            15.13.2.2. By Treatment

            15.13.2.3. By End User

    15.14. Australia

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Type

            15.14.2.2. By Treatment

            15.14.2.3. By End User

    15.15. New Zealand

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Type

            15.15.2.2. By Treatment

            15.15.2.3. By End User

    15.16. China

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Type

            15.16.2.2. By Treatment

            15.16.2.3. By End User

    15.17. Japan

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Type

            15.17.2.2. By Treatment

            15.17.2.3. By End User

    15.18. South Korea

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Type

            15.18.2.2. By Treatment

            15.18.2.3. By End User

    15.19. GCC Countries

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Type

            15.19.2.2. By Treatment

            15.19.2.3. By End User

    15.20. South Africa

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Type

            15.20.2.2. By Treatment

            15.20.2.3. By End User

    15.21. Israel

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Type

            15.21.2.2. By Treatment

            15.21.2.3. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Type

        16.3.3. By Treatment

        16.3.4. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Pfizer Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. AstraZeneca plc

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. F. Hoffmann-La Roche Ltd.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Eli Lilly and Company

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Boehringer Ingelheim GMBH

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Novartis AG

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Bristol-Myers Squibb Company

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Merck & Co., Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Celgene Corp.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Sun Pharmaceutical Industries Ltd.

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Lung Cancer Surgery Market

November 2024

REP-GB-396

252 pages

Healthcare

Lung Cancer Therapeutics Market

November 2024

REP-GB-422

250 pages

Healthcare

Lung Disease Therapeutics Market

July 2023

REP-GB-4290

306 pages

Healthcare

Lung Biopsy Systems Market

May 2022

REP-GB-9349

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Non-Small Cell Lung Carcinoma (NSCLC) Market

Schedule a Call